Table 1.
The Clinical Characteristics of the 68 Patients With Advanced Hepatocellular Carcinoma.
| Variables | Number of patients | Percentage |
|---|---|---|
| Age (years) | ||
| <65 | 30 | 44.1 |
| ≥65 | 38 | 55.9 |
| Sex | ||
| Male | 56 | 82.4 |
| Female | 12 | 17.6 |
| ECOG-PS | ||
| 0 | 10 | 14.7 |
| 1 | 40 | 58.8 |
| 2 | 10 | 14.7 |
| 3 | 8 | 11.8 |
| Childs-Pugh class | ||
| A | 50 | 73.5 |
| B | 18 | 26.5 |
| Hepatitis B virus infection | ||
| Yes | 49 | 72.1 |
| No | 19 | 27.9 |
| Liver cirrhosis | ||
| Yes | 28 | 41.2 |
| No | 40 | 58.8 |
| AFP (µg/L) | ||
| ≥400 | 24 | 35.3 |
| <400 | 44 | 64.7 |
| Tumor size (cm) | ||
| <3 | 14 | 20.6 |
| 3-5 | 8 | 11.8 |
| 5-10 | 26 | 38.2 |
| ≥10 | 20 | 29.4 |
| PVTT | ||
| Yes | 20 | 29.4 |
| No | 48 | 70.6 |
| Extrahepatic spread | ||
| Yes | 54 | 79.4 |
| No | 14 | 20.6 |
| Involved disease sites per patient | ||
| 1 | 36 | 52.9 |
| 2 | 22 | 32.4 |
| ≥3 | 10 | 14.7 |
| Previous treatment | ||
| No | 18 | 26.5 |
| Sur | 22 | 32.4 |
| TACE | 23 | 33.8 |
| RF | 4 | 5.9 |
| Che | 5 | 7.4 |
| MTT | 6 | 8.8 |
| AJCC stage | ||
| IIIb | 10 | 14.7 |
| Iva | 42 | 61.8 |
| IVb | 16 | 23.5 |
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group–Performance Status; PVTT, portal vein tumor thrombus; Sur, surgical resection; TACE, transcatheter arterial chemoembolization; RF, radiofrequency; Che, chemotherapy; MTT: molecular targeted therapy; AJCC, American Joint Committee on Cancer.